Results 211 to 220 of about 2,080,423 (380)

Turning Slowly Predicts Future Diagnosis of Parkinson's Disease: A Decade‐Long Longitudinal Analysis

open access: yesAnnals of Neurology, EarlyView.
Objective Wearable technology allows accurate measurement of turning while walking, with cross‐sectional studies indicating that difficulty turning presents even in preclinical phases of Parkinson's disease. The aim of our study was to quantify rate of change of turning performance in a cohort of older adults, and test whether turning decline can ...
Morad Elshehabi   +9 more
wiley   +1 more source

Antidepressant and Anxiolytic Effects of L-Methionine in the WAG/Rij Rat Model of Depression Comorbid with Absence Epilepsy. [PDF]

open access: yesInt J Mol Sci, 2023
Sarkisova KY   +5 more
europepmc   +1 more source

Second monotherapy in childhood absence epilepsy

open access: yesNeurology, 2017
A. Cnaan   +8 more
semanticscholar   +1 more source

Pro‐Inflammatory c‐Met+ CD4 T Cells in Multiple Sclerosis

open access: yesAnnals of Neurology, EarlyView.
Objective Hepatocyte growth factor (HGF) binds exclusively the c‐Met surface receptor, and the HGF/c‐Met axis regulates T cell function in autoimmune diseases. We analyzed c‐Met expression on human CD4 T cells in the blood and cerebrospinal fluid (CSF) from patients with multiple sclerosis (MS) versus non‐inflammatory neurological disease (NIND), to ...
Gautier Breville   +6 more
wiley   +1 more source

Phenotypic Classification of Scalp High-Frequency Oscillations in Absence Epilepsy Based on Multiple Characteristics Using K-Means Clustering. [PDF]

open access: yesBioengineering (Basel)
Maeda K   +10 more
europepmc   +1 more source

Perampanel and childhood absence epilepsy: A real life experience. [PDF]

open access: yesFront Neurol, 2022
Operto FF   +14 more
europepmc   +1 more source

Back Again to the Future: A New Era for Cerebroprotection

open access: yesAnnals of Neurology, EarlyView.
Cerebroprotection is a fresh framework for designing neurological therapy that targets glia and vascular cells, in addition to neurons. In the future, successful cerebroprotection will involve targeting all elements of the neurovascular unit. Preclinical trials must include functional outcomes, as well as lesion morphometry.
Patrick Lyden
wiley   +1 more source

Home - About - Disclaimer - Privacy